---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016735"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:34:51.056642+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive

## Summary
- Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.
- Total revenue of $19.0M, up from $1.7M year-over-year, driven by $17.9M licensing revenue.
- Cash, equivalents and marketable securities of $248.1M as of Sep 30, 2022; sufficient to fund operations through end of 2025.
- Phase 2a enrollment completed for zunsemetinib in hidradenitis suppurativa (95 patients); topline data expected mid-first half 2023.
- ATI-2138 Phase 1 SAD trial completed; generally well-tolerated, dose-dependent ITK/JAK3 inhibition; ulcerative colitis selected as first target; new IND submitted.

## SEC filing metadata
- accession: 0001558370-22-016735
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/0001558370-22-016735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/acrs-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016735
- JSON: https://secwatch.observer/filing/0001558370-22-016735.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016735.txt

## Key facts
- Earnings Releases
  Aclaris Therapeutics, Inc. reported financial results for the quarter and nine months ended September 30, 2022.
  - Period: the quarter and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837022016735/0001558370-22-016735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.